DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click
HERE to register or log in.
Accession Number:
AD1013500
Title:
A New Paradigm for the Treatment of Ovarian Cancer: The Use of Epigenetic Therapy to Sensitize Patients to Immunotherapy and Chemotherapy
Descriptive Note:
Technical Report,30 Sep 2014,29 Sep 2015
Corporate Author:
The Johns Hopkins University Baltimore United States
Report Date:
2015-10-01
Pagination or Media Count:
67.0
Abstract:
The overall goal of this project remains to bring epigenetic therapy strategies to have major impact forthe management of advanced ovarian cancer OC. In the first year, we have made exciting advances for this purpose and especially for the concept of utilizing low dose epigenetic therapy to target DNA demethylation and histone deacetylase inhibition HDACi to maximize responses to immune checkpoint therapy. We identified, from studies of multiple OC cell lines how low doses of the DNA demethylation agents, azacytidine AZA and deoxy-azacytidine DAC induce a deep immune attraction signature.
Distribution Statement:
APPROVED FOR PUBLIC RELEASE
